Results 191 to 200 of about 8,795,233 (257)

Fecal microbiome and metabolome dynamics during immunotherapy-based total neoadjuvant therapy in rectal cancer: associations with treatment response and toxicity. [PDF]

Front Immunol
Lu W, Wang Y, Zhang J, Li Y, Huang L, Yang W, Zhou S, Zhou M, Chen Y, Wu R, Wang Y, Zhang H, Wan J, Xia F, Zhang Z, Shen L.   +15 more
europepmc   +1 more source

Estimation of Subtype‐Specific Tumour Growth Rate Distributions and Interval Cancer Proportions in Breast Cancer Using Biology‐Inspired Natural History Models

International Journal of Cancer, EarlyView.
ABSTRACT Breast cancer progression varies across molecular subtypes, influencing detection rates and prognosis. Differences in the proportion of interval cancers (PIC)—cancers detected symptomatically between scheduled screening rounds—have been observed across subtypes, likely reflecting heterogeneity in tumour growth dynamics. We applied a continuous‐
Letizia Orsini, Yuqi Zhang, Kamila Czene, Keith Humphreys   +3 more
wiley   +1 more source

Total neoadjuvant therapy in rectal cancer: Challenging traditions without compromising surgical safety. [PDF]

World J Gastrointest Oncol
Karmakar R, Kandalkar A, Mukundan A.
europepmc   +1 more source

Pretreatment EBV‐DNA/TLG‐Based Risk Stratification Is Associated With Survival Outcomes in Nonmetastatic Nasopharyngeal Carcinoma: An Exploratory Study

International Journal of Cancer, EarlyView.
ABSTRACT Whether combining pretreatment plasma Epstein–Barr virus DNA (EBV‐DNA) with 18F‐FDG PET/CT‐derived total lesion glycolysis (TLG) improves prognostic stratification in nonmetastatic nasopharyngeal carcinoma (NPC) is unclear, particularly in nonendemic populations.
Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Nazlı Ünsal, Recep Bekiş, Büşra Tozduman, Özgür Appak, Ayşe Demiral, Oğuz Çetinayak   +7 more
wiley   +1 more source

Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. [PDF]

JAMA Oncol
Audisio A, Gallio C, Velenik V, Meillat H, Ruiz-Garcia E, Riesco MC, Alecha JS, Rasschaert G, Carvalho C, Randrian V, Kirac I, Hernando J, Artaç M, O'Connor JM, Waldhorn I, Braam PM, Shamseddine A, Moretto R, De la Pinta C, De Felice F, Dulskas A, Páez López-Bravo D, Vanden Bulcke A, Bock F, Deleporte A, Van Den Eynde M, Geboes KP, Loi M, Messina M, Houlzé-Laroye C, Puccini A, Pastorino A, Papamichael D, Fiore M, Sur D, Eid M, Antoun C, Salati M, Garajovà I, Jakubauskas M, Tomášek J, Sousa Pinto CM, Schwingel J, Morano F, Adams RA, Dermine A, Chau A, Javed MA, Ghidini M, Fiorica F, Montenegro P, Petrillo A, Spolverato G, Mulet Margalef N, Diaz M, Baratelli C, Puleo F, Karampeazis A, Sert F, Gilliaux Q, De Stefano A, Liberale G, Moretti L, Martinive P, Deltuvaite Thomas V, Staggs V, Saad ED, Van Laethem JL, Sclafani F, International Real-World TNT Study Consortium.   +69 more
europepmc   +2 more sources

An exploratory integrative analysis of plasma transcriptomic and proteomic predictors of response to total neoadjuvant therapy in locally advanced rectal cancer. [PDF]

Front Oncol
Zhu Z, Wen K, Zou B, Kang Y, Chen J, Zhu B, Fan L, Huang H.   +7 more
europepmc   +1 more source

Incidence and Predictors of Immune‐Related Hypothyroidism Under Pembrolizumab Across Gynecologic Malignancies and Melanoma: A Real‐World Cohort Study

International Journal of Cancer, EarlyView.
ABSTRACT Immune checkpoint inhibitors (ICIs) frequently cause thyroid immune‐related adverse events (irAEs). Permanent hypothyroidism, the clinically most relevant phenotype, requires lifelong hormone replacement. We investigated its incidence, course, risk factors, and prognostic relevance under pembrolizumab.
Freya Koffka, Johann Kornowski, Elena Laakmann, Barbara Schmalfeldt, Tim Zell, Glenn Geidel, Christoffer Gebhardt, Pia Roser, Volkmar Müller, Julian Kött   +9 more
wiley   +1 more source

Improved Prediction of Colon Cancer Recurrence Using the ColoNode mRNA Test: A 5‐Year Survival Analysis

International Journal of Cancer, EarlyView.
ABSTRACT Twenty‐five percent of colon cancer patients having curative surgery will recur. Most of them will die from distant metastasis partly due to shortcomings of routine histopathological analysis, that is, undetected tumor cells in the regional lymph node field.
Basel Sitohy, Gudrun Lindmark, Anne Israelsson, Lina Olsson, Tamer Roshdy, Joel Blomqvist, Sara Kero, Mattias Söderholm, Annamaria Turi, Thorbjörn Sakari, Michiel Dooper, George Dafnis, Pehr Forsberg, Susanne Skovsted, Maria Walldén, Chih‐Han Kung, Martin Rutegård, Johanna Nordmyr, Måns Muhrbeck, Sten Hammarström, Marie‐Louise Hammarström   +20 more
wiley   +1 more source

Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study. [PDF]

Discov Oncol
Sütcüoğlu O, Akdoğan O, Onur İD, Çiftçi A, Alkan A, Majidova N, Şahin E, Yıldıran GS, Taşçı EŞ, Kavgacı G, Genç Ö, Dilek MS, Okumuş NÖ, Özkan FE, Selvi O, Gür HB, Sekmek S, Karataş F, Dişli ŞY, Avcı N, Menekşe S, Erciyestepe M, Kut E, Alkan S, Ersoy M, İnal A, Tatlı AM, Aslan F, Türkmen E, Öksüz DÇ, Şakalar T, Aydın SG, Özkanlı G, Sakin A, Yılmaz B, Güren AK, Aykan MB, Köş FT, Araz M, Erdoğan AP, Hacıbekiroğlu İ, Yıldız İ, Kaplan MA, Demir H, Yalçın S, Dizdar Ö, Tanrıverdi Ö, Kaya DM, Doğan M, Özdemir N.   +49 more
europepmc   +1 more source

Perioperative Avelumab and Chemotherapy for Gastroesophageal Adenocarcinoma: Long‐Term Survival Outcomes

International Journal of Cancer, EarlyView.
ABSTRACT Long‐term survival data for patients with locally advanced gastro‐esophageal adenocarcinoma (GEA) treated with neoadjuvant chemoimmunotherapy are lacking. We describe the long‐term disease‐free survival (DFS) and overall survival (OS) outcomes of such patients treated with a novel neoadjuvant chemoimmunotherapy regimen, aDCF (avelumab with ...
Thierry Alcindor, James Tankel, Pierre‐Olivier Fiset, Mehrnoush Dehghani, Nicholas Bertos, Carmen Mueller, Jonathan Cools‐Lartigue, Sophie Camilleri‐Broet, Lorenzo Ferri   +8 more
wiley   +1 more source